OncoSec Medical Inc — Cyborg Score 4/10

Strategic Profile

The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. The proprietary ImmunoPulse technology is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors using electroporation, which involves the use of electrical pulses to increase the permeability of the cell membrane.

Cyborg Score Rationale

OncoSec operates as a subsidiary of Grand Pharmaceuticals with a promising immuno-oncology platform addressing significant cancer indications. However, the company trades OTC (not on major exchanges), has limited revenue generation history as a pre-commercialization biotech, and faces typical clinical development risks.

Top Insights

• Subsidiary status under Grand Pharmaceuticals provides financial backing and potential market access
• Lead candidate KEYNOTE-695 in Phase 2 trial for advanced melanoma; multiple pipeline programs in Phase 1
• Pipeline programs target metastatic melanoma, triple negative breast cancer and solid tumors
• OTC trading status reflects smaller market cap and liquidity constraints typical of early-stage biotech

Named Competitors

• Oncology Pipeline — Oncology and cell therapy programs
• RNAi Therapeutics — Gene therapy and RNA interference platform
• Gene Therapy — Inherited retinal disease and genetic therapies

Recent Developments

• (May 2026) Stock activity on OTCMKTS exchange with significant volatility

Open the full interactive OncoSec Medical Inc report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.